Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BNTX
BIONTECH SE
NASDAQ
$102.08
▼ DOWN 8.37% (-9.32)

KEY STATISTICS

Market Cap$25.64 B
52w High$124.00
52w Low$79.52
Dividend Yield1.33%
FrequencyIrregular
P/E-13.24
Volume3.07M
Shares Out.251.20M

COMPANY

LEADERSHIP

Ugur Sahin
CHIEF EXECUTIVE
Ugur Sahin

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 10, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
7,807

PRICE TARGET

Target High$155.00
Target Low$96.00
Target Median$135.00
Target Consensus$130.43

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$1.23B
NOV
3
TUE

PRICE

$102.08 ▼ DOWN 8.37% (−$9.32)
$101$102$104$1059:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM102.08

About BioNTech SE

https://www.biontech.com/de/de/home.html ↗

BioNTech SE is a Mainz-based biotech company developing immunotherapies and vaccines for cancer, infectious diseases, and rare conditions, with multiple candidates in various clinical trial phases and collaborations with major pharma partners.

INDUSTRY

Biotechnology

A PRODUCT BIONTECH SE IS KNOWN FOR

Comirnaty Omicron KP.2-adapted COVID-19 vaccine
Comirnaty Omicron KP.2-adapted COVID-19 vaccine

BioNTech's latest mRNA COVID-19 vaccine, developed with Pfizer, targets the Omicron KP.2 subvariant, showcasing their ongoing efforts to adapt to new virus strains and sustain protection.

COMPETITORS

COMPETITOR
GSK COMPARE
MRNA COMPARE
NVAX COMPARE
PFE COMPARE

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
DELAWARE$3.03B — — —
UNITED STATES$12.71B $3.01B ▼$1.85B ▼$1.79B ▼
GERMANY— $482.7M $706.9M ▲$759.1M ▲
IRELAND— — — $304.8M
Rest of the World— — $196.4M $11.1M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
101
LISTED HERE
26
RANKED BY POSITION SIZE
FBT
3.69% · 989.6K
IBB
0.72% · 682.4K
FNDF
0.11% · 266.1K
SPDW
0.03% · 97.7K
BBH
1.95% · 84.2K
EPAB.PA
0.25% · 83.1K
BBEU
0.09% · 73.0K
QQQJ
0.62% · 67.6K
ONEQ
0.03% · 28.6K
GNOM
2.93% · 25.2K
TPE.TO
0.05% · 20.4K
GERD.L
0.10% · 17.2K
BBP
1.51% · 16.2K
SILX
6.05% · 9.9K
XCHA.DE
0.04% · 7.7K
NXTE
1.48% · 7.6K
GERM
5.01% · 5.8K
GINN
0.28% · 5.1K
PR
PRAE
0.07% · 4.7K
BIB
0.42% · 4.2K
HELX
1.34% · 3.9K
APIE
0.03% · 3.0K
WDNA.L
0.93% · 2.8K
IQSI
0.07% · 2.0K
QQQN
1.04% · 1.7K
MSGR
5.76% · 1.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
420
TOP 12 OF 420 · RANKED BY POSITION SIZE
Metatron Capital Sicav Plc
242.5M sh · $204.1M
Baillie Gifford & Co
7.9M sh · $777.06M
Fmr LLC
7.6M sh · $704.56M
T. Rowe Price Investment Management, Inc.
5.9M sh · $520.49M
Flossbach Von Storch AG
4.2M sh · $417.17M
Primecap Management Co/Ca/
3.9M sh · $381.73M
Dodge & Cox
3.7M sh · $342.2M
Blackrock Inc.
1.9M sh · $152.32M
Blackrock, Inc.
1.9M sh · $172.6M
Pfizer Inc
1.7M sh · $163.55M
Bnp Paribas Arbitrage, Snc
1.7M sh · $146.81M
Temasek Holdings (Private) Ltd
1.5M sh · $140.14M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Valerie Hoyle
Valerie Hoyle
Sale (Full)
2025-08-07
 Josh Gottheimer
Josh Gottheimer
Sale (Full)
2024-09-03
 Ro Khanna
Ro Khanna
Sale
2022-01-20

INSIDER TRADES

★
DIRECTOR:
Schaffert Susanne
— · —
2026-06-26
★
DIRECTOR:
Low-Friedrich Iris Katharina
— · —
2026-06-26
★
OFFICER: CHIEF FINANCIAL OFFICER
Zapata Gomez Ramon
Purchase · 18.9K shares
2026-05-12
★
OFFICER: CHIEF OPERATING OFFICER
Poetting Sierk
Purchase · 12.6K shares
2026-05-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 2
OVERWEIGHT 2
HOLD 1
NEUTRAL 1
12 GRADES IN THE LAST 12 MONTHS
Citigroup BUY Evercore ISI Group OUTPERFORM Morgan Stanley OVERWEIGHT UBS BUY Canaccord Genuity BUY Wells Fargo OVERWEIGHT HC Wainwright & Co. BUY BMO Capital OUTPERFORM

SECTORS PEERS

PEERPRICE
NTRA$326.26COMPARE
TEVA$36.44COMPARE
DXCM$90.82COMPARE
BIIB$218.50COMPARE
RPRX$60.85COMPARE
PHG$26.72COMPARE
INCY$124.37COMPARE
STE$233.78COMPARE